KAM reports that 65 percent of GLP 1 users say the medication has altered what they eat when dining out
GLP-1 drugs (glucagon-like peptide-1 receptor agonists) are medications developed to treat both type 2 diabetes and obesity by correcting hormonal imbalance - stimulating insulin release and suppressing excess glucagon -to bring blood sugar back under control
As of May 2026, FDA has also proposed excluding compounded semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with a public comment period closing June 29, 2026
A myositis subset of antisynthetase syndrome can present with mildly elevated CK and interstitial lung disease
Regular evaluations are necessary when considering semaglutide as part of your medication regimen
GLP-1 medications can worsen existing GERD in some people, partly because slowed gastric emptying means more time for acid to reflux